Close Menu

NEW YORK (GenomeWeb) – As recognition has grown that existing immunotherapy biomarkers like PD-L1, microsatellite instability, and tumor mutational burden predict only some of the response variability seen in this new and highly popular class of drugs, pharma firms and independent researchers are broadening their attention, hoping to capture new features of the complex interaction between a cancer and the human immune system that can guide which patients to tre

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.